Drug intelligence / Profile preview

LY3053102

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Subcutaneous

Overview

LY3053102 is an investigational small molecule drug developed by Eli Lilly for the treatment of type 2 diabetes mellitus. It was administered subcutaneously and evaluated in clinical trials for its safety, tolerability, pharmacokinetics, and efficacy in both healthy volunteers and patients with type 2 diabetes. The precise mechanism of action remains unknown. Clinical development reached up to phase 2 but was ultimately terminated without approval for any indication.

Beyond the preview

Go deeper on LY3053102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3053102.

Explore the full profile